利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

109 条记录 (耗时 0.037 秒)

    Method of purifying therapeutic proteins
    7.
    发明授权
    Method of purifying therapeutic proteins 有权

    公开(公告)号：US09598461B2

    公开(公告)日：2017-03-21

    申请号：US14535085

    申请日：2014-11-06

    申请人： CSL Behring GmbH

    发明人： Hung Pham ,  Jeffrey Michael Hey ,  Darren Nguy

    IPC分类号： C07K1/22 ,  C07K1/18 ,  C07K1/20 ,  C07K14/75 ,  A61K38/36 ,  C07K14/745 ,  C07K14/755

    CPC分类号： A61K38/363 ,  A61K38/36 ,  C07K1/18 ,  C07K1/20 ,  C07K1/22 ,  C07K14/745 ,  C07K14/75 ,  C07K14/755

    摘要： The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in the solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or Factor VIII and/or VWF recovered by such methods, and uses thereof.

    USE OF C1-INHIBITOR FOR THE TREATMENT OF SECONDARY EDEMA OF THE CENTRAL NERVOUS SYSTEM
    10.
    发明申请
    USE OF C1-INHIBITOR FOR THE TREATMENT OF SECONDARY EDEMA OF THE CENTRAL NERVOUS SYSTEM 有权
    C1抑制剂治疗中枢神经系统二次治疗的用途

    公开(公告)号：US20140371425A1

    公开(公告)日：2014-12-18

    申请号：US14364097

    申请日：2012-12-21

    申请人： CSL BEHRING GMBH

    发明人： Christoph Kleinschnitz ,  Marc Nolte ,  Guido Stoll ,  Gerhard Dickneite ,  Stefan Schulte ,  Bernhard Nieswandt ,  Ingo Pragst

    IPC分类号： A61K38/57

    CPC分类号： A61K38/57

    摘要： The subject of the present invention is, in the most general aspect, the prevention and/or treatment of a secondary edema. In particular, the present invention relates to a C1-Inhibitor for use in a method of preventing the formation and/or reducing the size of a secondary edema of the central nervous system (CNS) in a subject wherein the subject has or has had at least one disorder selected from the group consisting of stroke, ischemic stroke, hemorrhagic stroke, perinatal stroke, traumatic brain injury and spinal cord injury. Preferably the secondary edema of the CNS is a secondary brain edema. Another subject of the present invention is the treatment of disorders associated with an increased permeability of the blood brain barrier or the blood spinal cord barrier. And a third subject is a plasma-derived C1-inhibitor for use in a method of preventing, reducing or treating brain ischemia-reperfusion injury.

    摘要翻译： 在最一般的方面，本发明的主题是预防和/或治疗二次水肿。 特别地，本发明涉及一种用于防止在受试者中具有或已经具有中枢神经系统（CNS）的中枢神经系统（CNS）的继发性水肿的形成和/或减小的方法的方法的C1抑制剂 选自中风，缺血性中风，出血性中风，围产期中风，创伤性脑损伤和脊髓损伤的至少一种障碍。 优选CNS的继发性水肿是继发性脑水肿。 本发明的另一主题是治疗与血脑屏障或血液脊髓屏障的渗透性增加相关的病症。 并且第三个受试者是用于预防，减少或治疗脑缺血 - 再灌注损伤的方法中的等离子体衍生的C1抑制剂。